Research compounds
Livagen
Lys-Glu-Asp-Ala, KEDA
Livagen is a synthetic tetrapeptide from the Khavinson bioregulator family, marketed for liver and immune function. It is not approved by the FDA or EMA.
Also known as: KEDA, Lys-Glu-Asp-Ala
- Status
- Livagen is a research compound and not approved by the FDA for human use.
- Evidence
- Anecdotal. Mostly community reports; there is no controlled human data.
- Half-life
- Not established.
- How it's taken
- Injection or oral capsule in non-clinical use
- Mechanism
- Immune modulation
How Livagen works
As with the other bioregulators, the proposed mechanism is tissue-specific modulation of gene expression through direct peptide interaction with DNA — here targeting hepatic tissue and lymphocytes. Some published work describes chromatin decondensation in lymphocytes. The mechanism has not been independently validated outside the originating group.
What research has looked at
- Published work from the originating group describes effects on lymphocyte chromatin structure.
- Its small size makes several routes of administration plausible.
- Long, if uncontrolled, history of use in Russia.
Evidence level: Anecdotal. Mostly community reports; there is no controlled human data. These are areas studied or reported, not promised effects.
Reported side effects and risks
- The mechanism has not been independently replicated and is not accepted pharmacology. No regulator has approved it, the human evidence base is limited, and material sold under this name is research chemical supply with unverified identity, purity, sterility and dose accuracy.
- No controlled Western clinical trials exist.
- Hepatoprotective and immune claims are unsupported by controlled human outcome data.
- Long-term safety in humans is unstudied.
Sources
- PubMed research on Khavinson peptide bioregulator livagen chromatin · NIH · National Library of Medicine
- DrugBank record for livagen · DrugBank
- Active clinical trials for livagen · U.S. National Library of Medicine
Track Livagen in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
Livagen FAQ
What is Livagen?
Livagen is a synthetic tetrapeptide from the Khavinson bioregulator family, marketed for liver and immune function. It is not approved by the FDA or EMA.
How does Livagen work?
As with the other bioregulators, the proposed mechanism is tissue-specific modulation of gene expression through direct peptide interaction with DNA — here targeting hepatic tissue and lymphocytes. Some published work describes chromatin decondensation in lymphocytes. The mechanism has not been independently validated outside the originating group.
Is Livagen FDA approved?
No. Livagen is a research compound and not approved by the FDA for human use. Evidence level: anecdotal. Mostly community reports; there is no controlled human data.
How is Livagen taken?
Injection or oral capsule in non-clinical use.
What side effects have been reported with Livagen?
Reported in the sources: The mechanism has not been independently replicated and is not accepted pharmacology. No regulator has approved it, the human evidence base is limited, and material sold under this name is research chemical supply with unverified identity, purity, sterility and dose accuracy; No controlled Western clinical trials exist; Hepatoprotective and immune claims are unsupported by controlled human outcome data; Long-term safety in humans is unstudied.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.